Recent Publications

Research Papers

(Peer-reviewed)

    1. Kim, J., Chou, T.-F., Griesgraber, G. W., and Wagner, C. R. “Direct measurement of nucleoside monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LCESI- MS/MS.” Molecular Pharmaceutics 2004, 1, 102 - 111.
    2. Chou, T.-F., Bieganowski, P., Shilinski, K., Cheng, J., Brenner, C., and Wagner, C. R. “31P-NMR and genetic analysis establish hinT as the only Escherichia coli purine nucleoside phosphoramidase and as essential for growth under high salt conditions.” J. Biol. Chem. 2005, 280, 15356 - 15361.
    3. Carlson, J. C. T., Jena, S. S., Flenniken, F., Chou, T.-F., Siegel, R. A., and Wagner, C. R. “Chemically controlled self-assembly of protein nanorings.” J. Am. Chem. Soc. 2006, 128, 7630 - 7638.
    4. Chou, T.-F., and Wagner, C. R. “Lysyl-tRNA synthetase generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins (Hints).” J. Biol. Chem. 2007, 282, 4719 - 4727.
    5. Chou, T.-F., Baraniak, J., Kaczmarek, R., Zhou, X., Cheng, J., Ghosh, B., and Wagner, C. R. “Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and E. coli histidine triad nucleotide binding proteins (Hint1).” Molecular Pharmaceutics 2007, 4, 208 - 217.
    6. Chou, T.-F., Tikh, I. B., Horta, B.A.C., Ghosh, B., de Alencastro, R.B., and Wagner, C. R. “Engineered monomeric human histidine triad nucleotide binding protein 1 hydrolyzes fluorogenic acyl -adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate.” J. Biol. Chem. 2007, 282, 15137 - 15147.
    7. Chou, T.-F., Cheng, J, Tikh, I. B., and Wagner, C. R. “Evidence that human histidine triad nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT) superfamily.” J. Mol. Biol.2007, 373, 978 - 989.
    8. Chou, T.-F., Sham, Y. Y., and Wagner, C. R. “The Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity.” Biochemistry, 2007, 46, 13074 - 13079.
    9. Ghosh, P., Chen, J., Chou, T.-F., Jia, Y., Avdulov, S., Bitterman, P. B., Polunovsky, V. A., and Wagner, C.R. “Expression, purification and characterization of recombinant mouse initiation factor eIF-4E as a dihydrofolate reductase (DHFR) fusion protein”. Protein Expression and Purification 2008, 60, 132 - 139.
    10. Chou, T.-F., So, C., White, B.R., Carlson, J.C.T., Sarikaya, M., and Wagner, C.R. “Enzyme nanorings” ACS Nano 2008, 2, 2519 - 2525.
    11. Cheng J, Zhou X, Chou T.-F, Ghosh B, Liu B, Wagner CR. “Identification of the amino acid-AZT-phosphoramidase by affinity T7 phage display selection. Bioorg. Med. Chem. Lett. 2009, 19, 6379 - 6381.
    12. Bardaweel, S., Pace, J., Chou, T.-F., Cody, V., and Wagner, C.R. “Probing the impact of the echinT c-terminal domain on structure and catalysis.” J. Mol. Biol. 2010, 404, 627 - 638.
    13. Chou, T.-F.*, and Deshaies, R. J*. “Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J. Biol. Chem. 2011, 286, 16546 - 16554. *Co-corresponding authors
    14. Chou, T.-F.*, Brown, S. J., Minond, D., Nordin, B.E., Li, K., Jones, A.C., Chase, P.,Porubsky, P. R., Stoltz, B.M., Schoenen, F. J., Patricelli, M.P., Hodder, P., Rosen, H., and Deshaies, R. J*. “Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways” Proc. Natl. Acad. Sci. USA. 2011, 108, 4834 - 4839. *Co-corresponding authors
    15. Birkus, G., Kutty, N.,Frey, C.R., Shribata, R. Chou, T.-F., Wagner, C.R., McDermott, M., and Cihlar, T. “Role of cathepsin A and lysosomes in the intracellular activation of novel anti-papillomavirus agent GS-9191. Antimicrob. Agents Chemother. 2011, 55, 2166 - 2173.
    16. Chou, T.-F*., and Deshaies, R. J*. “Development of p97 AAA ATPase inhibitors. Autophagy. 2011, 7, 1091-1092. *Co-corresponding authors
    17. Bardaweel, S., Ghosh, B., Chou, T.-F., Sadowsky, M.J., and Wagner, C.R. “E. coli histidine triad nucleotide binding protein 1 (ecHinT) is a catalytic regulator of D-alanine dehydrogenase (DadA) activity in vivo. PLoS One. 2011, 6, e20897. DOI: 10.1002/cmdc.201200520.
    18. Chou, T.-F*., Li, K., Frankowski, K., Schoenen, F. J., and Deshaies, R. J*. “Structure- Activity Relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase” ChemMedChem. 2013, 8,297-312. *Co-corresponding authors
    19. Zhou, X., Chou, T.-F, Aubol, B.E., Park, C. J.,Wolfenden, R., Adams, J. and Wagner, C.R. “Kinetic Mechanism of Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) ”Biochemistry, 2013, 52, 3588-3600
    20. Chou, T.-F*, Bulfer, S. L., Weihl, C.C., Li, K., Lis, L. G., Walters, M. A., Schoenen, F.J., Lin, H. J., Deshaies, R. J, and Arkin, M. R. “Specific Inhibition of p97/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase domains” J. Mol. Biol. 2014, 426, 2886-2899. *Corresponding author
    21. Gonzalez, M.A., Feely, S., Speziani, F., Strickland, A., Danzi, M., Bacon, C., Youjin Lee, Y., Chou, T.-F, Blanton, S.H., Weihl, C.C., Zuchner, S., Shy, M. “A Novel Mutation in VCP Causes Charcot-Marie-Tooth Type 2 Disease” Brain, 2014, PMID: 25125609.
    22. Sapir, A., Tsur, A., Koorman, T., Ching, K., Bardenheier, A., Podolsky, L., Bening-Abu-Shach, U., Boxem, M., Chou, T.-F, Broday, L., and Sternberg, P.W. “Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging” Proc. Natl. Acad. Sci. USA. 2014, 111, E3880-3889.
    23. Kato, M., Chou, T.-F, Yu, C.Z., Demodena, J., and Sternberg, P.W. “"LINKIN, a new transmembrane protein necessary for cell adhesion” eLife. 2014, e04449. (PMID:25437307)
    24. Fang, C., Gui, L., Zhang, X., Moen, D.R., Li, K., Frankowski, K. J., Lin, H.J., Schoene, F.J., and Chou, T.-F “Evaluating p97 inhibitor analogues for their domain-selectivity and potency against the p97-p47 complex” ChemMedChem, 2015, 10, 52-56. (PMID: 25377500)
    25. Weihl, C. C., Baloh, R. H., Lee, Y., Chou, T.-F, Pittman, S. K., Lopate, G., Allred, P., Jockel-Balsarotti, J., Pestronk , A., and Harms, M. B. “Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord., 2015 Apr;25(4):289-296.
    26. Zhang, X., Gui, L., Zhang, X., Bulfer, S. L., Sanghez, V., Wong, D., Lee, Y.J., Lehmann, L., Lee, J. S., Shih, P.-Y., Lin, H. J., Iacovino, M., Weihl, C. C., Arkin, M. R., Wang, T., Chou, T.-F. “Altered cofactor regulation with disease associated p97/VCP mutations.” Proc. Natl. Acad. Sci. USA, 2015, 112, E1705-1714.
    27. Jerath, N.U., Crockett, C.D., Moore, S.A., Shy, M.E., Weihl, C.C, Chou, T.-F, Gonzalez, M.A., Zuckner, S., and Swenson A. “Rare Manifestation of a c.290 C>T, p.Gly97Glu VCP Mutation.” Case Rep Genet. 2015; 2015:239167.
    28. Liu, M., Lin, L., Gebremariam, T., Luo, G., Skory, C. D., French, S. W., Chou, T.-F,, Edwards, J.E., Jr., and Ibrahim, A. S. (2015) “Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine.” PLoS Pathog. 2015, 11, e1004842.
    29. Gui, L , Zhang, X, Li, K., Frankowski, K., Li, S., Wong, D., Moen, D.R, Porubsky, P.R., Lin, H. J., Schoene, F.J., Chou, T.-F. “Evaluating p97 Inhibitor Analogues for Potency against p97-p37 and p97-Npl4-Ufd1 Complexes.” ChemMedChem, 2016, 11, 953-957.
    30. Bulfer, S. L., Chou, T.-F., Arkin, M. R. “p97 disease mutations modulate nucleotide-induced conformation to alter protein-protein interactions” ACS Chem Biol. 2016, 11, 2112-2116.
    31. Perez C., Li J., Parlati F., Rouffet M., Ma Y., Mackinnon A.L., Chou, T.-F., Deshaies R. J., Cohen S. M. “Discovery of an Inhibitor of the Proteasome Subunit Rpn11.” J. Med. Chem. 2017, 60, 1343-1361.
    32. Segura-Cabrera, A., Tripathi, R., Zhang, X, Gui, L, Chou, T.-F, Komurov, K. “A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase“ Scientific Reports. 2017, 7,44912
    33. Lee, Y.J., Chou, T.-F., Pittman, S.K., Weihl, C. C. "Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA domain Ubiquitination." Cell Reports 2017, 19,188-202
    34. Shah, R.#, Chou, T.-F.#, Maize, K. M, , Strom, A., Finzel, B. C. and Wanger, C. R. ”Inhibition by Divalent Metal Ions of Human Histidine Triad Nucleotide Binding Protein1 (hHint1), a Regulator of Opioid Analgesia and Neuropathic Pain.” Biochemical and Biophysical Research Communications (BBRC). 2017, 491,760-766 # Both authors contributed equally.
    35. Bastola, P., Wang, F., Schaich, M.A., Gan, T., Freudenthal, B.E., Chou, T.-F., Chien, J., “Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors.” Cell Death Discovery. 2017, 60(7):3217.
    36. Perez, C, Li, J., Parlati, F., Rouffet, M., Ma, Y., Zhou, H. J., Mackinnon, A. L., Chou, T.-F., Deshaies, R. J., Cohen, S. M., "Correction to Discovery of an Inhibitor of the Proteasome Subunit Rpn11." Journal of medicinal chemistry. 2017; 60(7):3217.
    37. Sanghez, V., Luzzi, A., Clarke, D., Kee, D., Buder, S., Rux, D., Osawa, M., Madrenas, J., Chou, T.-F., Kyba, M., Iacovino, M. “Notch activation is required for downregulation of HoxA3-dependent endothelial cell phenotype during blood formation.” PLoS One, 2017, 12, e0186818.
    38. Nakasone, M.A., Lewis, T.A., Walker, O., Thakur, A., Mansour, W., Castañeda, C.A., Goeckeler-Fried, J.L., Parlati, F., Chou, T.-F., Hayat, O., Zhang, D., Camara, C.M., Bonn, S.M., Nowicka, U.K., Krueger, S., Glickman, M.H., Brodsky, J.L., Deshaies, R.J., Fushman, D. “Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway.” Structure. 2017, 25,1839-1855.
    39. Sanghez, V., Chen, M., Li, S., Chou, T.-F., Iacovino, M., Lin, H. J., Lasky, J. L., and Panosyan, E. H., “Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma.” Anticancer Research, 2018, 38, 2627-2634.
    40. Li J, Zhang Y, Da Silva Sil Dos Santos B, Wang F, Ma Y, Perez C, Yang Y, Peng J, Cohen SM, Chou, T.-F., Hilton ST, Deshaies RJ. “Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11.” Cell Chem Biol. 2018, pii: S2451- 9456(18)30264-2. doi: 10.1016/j.chembiol.2018.07.012.
    41. LaPorte MG, Burnett JC, Colombo R, Bulfer SL, Alverez C, Chou, T.-F., Neitz RJ, Green N, Moore WJ, Yue Z, Li S, Arkin MR, Wipf P, Huryn DM. “Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97.” ACS Med Chem Lett. 2018, 9(11):1075-1081.
    42. Wang F., Li S., Gan T., Stott G.M., Flint A., and Chou T-F. "Allosteric p97 inhibitors can overcome resistance to ATP-competitive p97 inhibitors for potential anti-cancer therapy." ChemMedChem , 2020. DOI: 10.1002/cmdc.201900722